MelissaMorrison(Cable)ToyosMD

Ophthalmology • Nashville, TN

Discover Vision Centers

Join to view full profile

Dr. Toyos is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Toyos' full profile

Already have an account?

Office
2204 Crestmoor Rd
Nashville, TN 37215
Phone+1 615-327-4015

Fax+1 615-327-4080
Is this information wrong?

Education & Training

University of Missouri-Kansas City School of MedicineResidency, Ophthalmology, 1996 - 1999
University of Missouri-Kansas City School of MedicineInternship, Internal Medicine, 1995 - 1996
LSU School of Medicine in ShreveportClass of 1995

Certifications & Licensure

TN State Medical License 2014 - 2025
NY State Medical License 2019 - 2024
MS State Medical License 2020 - 2024
MO State Medical License 1996 - 2015
KS State Medical License 1999 - 2014
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012-2013
Fellow (FAAO) American Academy of Ophthalmology

Clinical Trials

Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery Start of enrollment: 2011 Apr 01
Completed
Efficacy and Safety of Meibomian Gland Dysfunction and Dry Eye With an LED Blue Treatment Device Start of enrollment: 2019 Feb 12
Withdrawn
Not Applicable

Publications & Presentations

PubMed

3 citations
Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification
Melissa M. Toyos> ;Ophthalmology and Therapy. 2019 Mar 13
1 citations
Letter to the Editor Re "Multicenter Study of Intense Pulsed Light Therapy for Patients With Refractory Meibomian Gland Dysfunction".
Melissa M Toyos> ;Cornea. 2019 May 1
34 citations
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease
Joseph Tauber, Barry A Schechter, Jason Bacharach, Melissa M Toyos, Robert Smyth-Medina, Sidney L Weiss, Jodi Luchs> ;Clinical Ophthalmology. 2018 Oct 2
13 citations
Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial.
Kelly K. Nichols, Edward J. Holland, Melissa M Toyos, James H Peace, Parag A. Majmudar, Aparna Raychaudhuri, Mohamed Hamdani, Monica Roy, Amir H. Shojaei> ;Clinical Ophthalmology. 2018 Jan 31
9 citations
Difluprednate 0.05% versus Prednisolone Acetate 1% for Endogenous Anterior Uveitis: Pooled Efficacy Analysis of Two Phase 3 Studies.
John D. Sheppard, C. Stephen Foster, Melissa Toyos, Kerry L. Markwardt, Robert Da Vanzo, Thomas E. Flynn, John H. Kempen> ;Ocular Immunology and Inflammation. 2019 Jan 1
12 citations
Continuous Wave Fractional CO2 Laser for the Treatment of Upper Eyelid Dermatochalasis and Periorbital Rejuvenation.
Melissa Morrison Toyos> ;Photomedicine and Laser Surgery. 2017 May 1
36 citations
Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study.
John D. Sheppard, Melissa Toyos, John H. Kempen, Paramjit Kaur, C. Stephen Foster> ;Investigative Ophthalmology & Visual Science. 2014 May 6
Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain.
> ;Curr Med Res Opin. 2011 Sep
On the front lines: What's new in botox and facial fillers.
Melissa Morrison Cable> ;Missouri Medicine. 2010 Nov 1
A theory of evolution--step by step: how women are changing the workforce.
Melissa Morrison Cable> ;Missouri Medicine. 2008 Sep 1
Join now to see all

Press Mentions

Taking Care of Your Eyes in the Golden Age of Screen TimeJanuary 19th, 2021
Dompé Announces First Patient Enrollment in Phase 2b Clinical Trial Investigating Novel Mechanism of Action in Moderate to Severe Dry Eye DiseaseJune 25th, 2019